POCN MASH Center of Excellence – POCN MASH Center of Excellence

Metabolic Dysfunction-Associated Steatohepatitis Resources Chosen by Advanced Practice Providers

Clinical guidelines
Patient support and education resources
Research updates

GLP-1 Agonists’ Potential for Fibrosis Regression

In a recent review, researchers examined the molecular and clinical effects of glucagon-like peptide 1 (GLP-1) receptor agonists in treating metabolic dysfunction-associated steatotic liver disease (SLD)....

Corrie Berk,

DNP, MBA, APRN
Nurse Practitioner, Texas Liver Institute

Resmetirom and Advanced Liver Fibrosis

Resmetirom (MGL-3196) received accelerated FDA approval in March 2024 for treating MASH with moderate to advanced liver fibrosis (F2-F3). This...

CURATED BY:
Corrie Berk,
DNP, MBA, APRN

Resmetirom FDA-Approved for MASH

In 2024, resmetirom (MGL-3196) became the first FDA-approved drug for MASH, demonstrating significant efficacy in resolving MASH without worsening fibrosis...

CURATED BY:
Corrie Berk,
DNP, MBA, APRN

MASLD: The Growing Need for Early Intervention

MASLD (metabolic-associated steatotic liver disease) is the most common chronic liver disease in the US, affecting an estimated 31% of...

CURATED BY:
Corrie Berk,
DNP, MBA, APRN

Physician Associate and Nurse Practitioner Contributors to the Metabolic Dysfunction-Associated Steatohepatitis Center of Excellence

POCN’s Metabolic Dysfunction-Associated Steatohepatitis Center of Excellence is curated by practicing clinical physician associates and nurse practitioners who review and select resources that are the most useful to their peers. They provide their expertise by hand-picking the latest content for advanced practice providers.